Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
'Dancing with the Stars' semifinals: How to watch Episode 10 tonight, where to stream, who's left and more - 2Elvis Presley's Infamous Pantera Shooting
- 3Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
- 4Mom warns of Christmas gift hazard as daughter recovers in hospital
- 5Hidden Island Cameras Capture Rare Tasmanian Species for the First Time Ever
- Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- The top astronomical discoveries of 2025
- Artemis II shares new lunar images while more than halfway to the moon
- A coup too far: Why Benin's rebel soldiers failed where others in the region succeeded
- Instructions to Augment the Presentation of Your Kona SUV
- Examination In progress into Abuse of Japanese Government-Supported Advance
- 6 Eyewear Brands Worth Purchasing
- The most effective method to Involve Handshakes for Compromise and Compromise
- Russia Creates New Military Branch Dedicated To Drone Warfare
